Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.
1 other identifier
interventional
31,546
40 countries
727
Brief Summary
The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint. Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4 cardiovascular-diseases
727 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2001
CompletedFirst Submitted
Initial submission to the registry
September 9, 2005
CompletedFirst Posted
Study publicly available on registry
September 12, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2008
CompletedResults Posted
Study results publicly available
August 25, 2009
CompletedMay 20, 2014
May 1, 2014
6.6 years
September 9, 2005
June 15, 2009
May 13, 2014
Conditions
Outcome Measures
Primary Outcomes (3)
ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.
56 months
ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients
ESRD is defined by initiation of dialysis, need for renal transplantation, or eGFR \<15 mL/min/1.73 m². Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline. These renal outcomes were not adjudicated (apart from death).
56 months
TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.
56 months
Secondary Outcomes (35)
ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke
56 months
ONTARGET. Cardiovascular Death
56 months
ONTARGET. Non-fatal Myocardial Infarction
56 months
ONTARGET. Non-fatal Stroke
56 months
ONTARGET. Hospitalization for Congestive Heart Failure
56 months
- +30 more secondary outcomes
Interventions
Eligibility Criteria
You may qualify if:
- Coronary Artery Disease: Previous Myocardial infarction(\> 2 days prior to informed consent), or stable or previous unstable angina (\> 30 days prior to informed consent) with documented multivessel coronary artery disease or a positive stress test, or multivessel Percutaneous Transluminal Coronary Angioplasty (\> 30 days prior to informed consent), or previous multivessel Coronary Artery Bypass Grafting without angina (if surgery performed \> 4 years prior to informed consent) or with recurrent angina after surgery.
- Other High Risk:
- Peripheral Arterial Disease: Previous limb bypass surgery or angioplasty or amputation, intermittent claudication on history with ankle/arm Blood Pressure ratio \< 0.8 on at least one side, or significant stenosis by angiography or non-invasive testing
- Previous stroke
- Transient ischemic Attack \> 7 days and \< 1 year prior to informed consent
- Diabetes Mellitus (types I or II): with evidence of end-organ damage (retinopathy, Left ventricular hypertrophy, micro or macro albuminuria), or any evidence of previous cardiac or vascular disease.
- No definite and specific indication or contraindication for any of the study treatments. Written informed consent.
You may not qualify if:
- A. Medication use:
- Inability to discontinue Angiotension Converting Enzyme (ACE) inhibitors or Angiotension 2 receptor antagonists (AIIAs).
- Patients with known hypersensitivity or intolerance to Angiotension 2 receptor antagonists (AIIAs) or Angiotension Converting Enzyme (ACE)inhibitors.
- NOTE: Patients with known intolerance to Angiotension Converting Enzyme inhibitor intolerance ( ACE-I) can be enrolled in the TRANSCEND study.
- B. Cardiovascular disease:
- Symptomatic congestive heart failure.
- Hemodynamically significant primary valvular or outflow tract obstruction (e.g. aortic or mitral valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic valve).
- Constrictive pericarditis.
- Complex congenital heart disease.
- Syncopal episodes of unknown etiology \< 3 months before informed consent.
- Planned cardiac surgery or angioplasty within three months.
- Uncontrolled hypertension on treatment (i.e.Blood pressure ( BP) \> 160/100).
- Heart transplant recipient.
- Strokes due to subarachnoid hemorrhage
- C. Other conditions:
- +14 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (732)
502.373.0256 Boehringer Ingelheim Investigational Site
Athens, Alabama, United States
502.373.0251 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
502.373.0182 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
502.373.0188 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
502.373.0189 Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States
502.373.0177 Boehringer Ingelheim Investigational Site
Tuscon, Arizona, United States
502.373.0209 Boehringer Ingelheim Investigational Site
Bentonville, Arkansas, United States
502.373.0173 Boehringer Ingelheim Investigational Site
Concord, California, United States
502.373.0266 Boehringer Ingelheim Investigational Site
Harbor City, California, United States
502.373.0283 Boehringer Ingelheim Investigational Site
Loma Linda, California, United States
502.373.0180 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
502.373.0175 Boehringer Ingelheim Investigational Site
Sacramento, California, United States
502.373.0165 Boehringer Ingelheim Investigational Site
San Diego, California, United States
502.373.0228 Boehringer Ingelheim Investigational Site
San Leandro, California, United States
502.373.0205 Boehringer Ingelheim Investigational Site
Sylmar, California, United States
502.373.0277 Boehringer Ingelheim Investigational Site
West Hills, California, United States
502.373.0226 Boehringer Ingelheim Investigational Site
Bridgeport, Connecticut, United States
502.373.0174 Boehringer Ingelheim Investigational Site
Farmington, Connecticut, United States
502.373.0258 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia, United States
502.373.0179 Boehringer Ingelheim Investigational Site
Gainesville, Florida, United States
502.373.0183 Boehringer Ingelheim Investigational Site
Palm Harbor, Florida, United States
502.373.0240 Boehringer Ingelheim Investigational Site
Panama City, Florida, United States
502.373.0171 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
502.373.0282 Boehringer Ingelheim Investigational Site
Vero Beach, Florida, United States
502.373.0214 Boehringer Ingelheim Investigational Site
Weston, Florida, United States
502.373.0161 Boehringer Ingelheim Investigational Site
Augusta, Georgia, United States
502.373.0193 Boehringer Ingelheim Investigational Site
Augusta, Georgia, United States
502.373.0201 Boehringer Ingelheim Investigational Site
Augusta, Georgia, United States
502.373.0223 Boehringer Ingelheim Investigational Site
Conyers, Georgia, United States
502.373.0268 Boehringer Ingelheim Investigational Site
Sandersville, Georgia, United States
502.373.0245 Boehringer Ingelheim Investigational Site
Savannah, Georgia, United States
502.373.0199 Boehringer Ingelheim Investigational Site
Tucker, Georgia, United States
502.373.0162 Boehringer Ingelheim Investigational Site
Valdosta, Georgia, United States
502.373.0203 Boehringer Ingelheim Investigational Site
Pocatello, Idaho, United States
502.373.0244 Boehringer Ingelheim Investigational Site
Burbank, Illinois, United States
502.373.0272 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
502.373.0217 Boehringer Ingelheim Investigational Site
Olympia Fields, Illinois, United States
502.373.0270 Boehringer Ingelheim Investigational Site
Des Moines, Iowa, United States
502.373.0167 Boehringer Ingelheim Investigational Site
Monroe, Louisiana, United States
502.373.0158 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana, United States
502.373.0247 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
502.373.0284 Boehringer Ingelheim Investigational Site
Boston, Massachusetts, United States
502.373.0229 Boehringer Ingelheim Investigational Site
Springfield, Massachusetts, United States
502.373.0237 Boehringer Ingelheim Investigational Site
Wyandotte, Michigan, United States
502.373.0208 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
502.373.0232 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
502.373.0231 Boehringer Ingelheim Investigational Site
Saint Paul, Minnesota, United States
502.373.0181 Boehringer Ingelheim Investigational Site
Biloxi, Mississippi, United States
502.373.0185 Boehringer Ingelheim Investigational Site
Cleveland, Mississippi, United States
502.373.0254 Boehringer Ingelheim Investigational Site
Jackson, Mississippi, United States
502.373.0195 Boehringer Ingelheim Investigational Site
Kansas City, Missouri, United States
502.373.0207 Boehringer Ingelheim Investigational Site
St Louis, Missouri, United States
502.373.0239 Boehringer Ingelheim Investigational Site
St Louis, Missouri, United States
502.373.0279 Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
502.373.0169 Boehringer Ingelheim Investigational Site
North Las Vegas, Nevada, United States
502.373.0157 Boehringer Ingelheim Investigational Site
Camden, New Jersey, United States
502.373.0202 Boehringer Ingelheim Investigational Site
East Orange, New Jersey, United States
502.373.0191 Boehringer Ingelheim Investigational Site
Newark, New Jersey, United States
502.373.0271 Boehringer Ingelheim Investigational Site
Westwood, New Jersey, United States
502.373.0213 Boehringer Ingelheim Investigational Site
Brooklyn, New York, United States
502.373.0230 Boehringer Ingelheim Investigational Site
Buffalo, New York, United States
502.373.0288 Boehringer Ingelheim Investigational Site
Kingston, New York, United States
502.373.0238 Boehringer Ingelheim Investigational Site
New York, New York, United States
502.373.0252 Boehringer Ingelheim Investigational Site
New York, New York, United States
502.373.0286 Boehringer Ingelheim Investigational Site
New York, New York, United States
502.373.0166 Boehringer Ingelheim Investigational Site
Northport, New York, United States
502.373.0156 Boehringer Ingelheim Investigational Site
Rochester, New York, United States
502.373.0264 Boehringer Ingelheim Investigational Site
Rochester, New York, United States
502.373.0227 Boehringer Ingelheim Investigational Site
Scarsdale, New York, United States
502.373.0150 Boehringer Ingelheim Investigational Site
The Bronx, New York, United States
502.373.0163 Boehringer Ingelheim Investigational Site
Westfield, New York, United States
502.373.0241 Boehringer Ingelheim Investigational Site
Williamsville, New York, United States
502.373.0273 Boehringer Ingelheim Investigational Site
Durham, North Carolina, United States
502.373.0261 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina, United States
502.373.0222 Boehringer Ingelheim Investigational Site
Fargo, North Dakota, United States
502.373.0155 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
502.373.0164 Boehringer Ingelheim Investigational Site
Cleveland, Ohio, United States
502.373.0168 Boehringer Ingelheim Investigational Site
Dayton, Ohio, United States
502.373.0159 Boehringer Ingelheim Investigational Site
Mansfield, Ohio, United States
502.373.0178 Boehringer Ingelheim Investigational Site
Oklahoma City, Ohio, United States
502.373.0259 Boehringer Ingelheim Investigational Site
Guthrie, Oklahoma, United States
502.373.0154 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma, United States
502.373.0152 Boehringer Ingelheim Investigational Site
Tulsa, Oklahoma, United States
502.373.0243 Boehringer Ingelheim Investigational Site
Portland, Oregon, United States
502.373.0265 Boehringer Ingelheim Investigational Site
Erie, Pennsylvania, United States
502.373.0153 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
502.373.0274 Boehringer Ingelheim Investigational Site
Sellersville, Pennsylvania, United States
502.373.0184 Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
502.373.0248 Boehringer Ingelheim Investigational Site
Columbia, South Carolina, United States
502.373.0172 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
502.373.0187 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
502.373.0219 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
502.373.0275 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
502.373.0221 Boehringer Ingelheim Investigational Site
Fort Worth, Texas, United States
502.373.0206 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
502.373.0234 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
502.373.0280 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
502.373.0249 Boehringer Ingelheim Investigational Site
Burke, Virginia, United States
502.373.0281 Boehringer Ingelheim Investigational Site
Seattle, Washington, United States
502.373.0212 Boehringer Ingelheim Investigational Site
Milwaukee, Wisconsin, United States
502.373.350 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.351 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.352 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.353 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.354 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.355 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.356 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.378 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.362 Boehringer Ingelheim Investigational Site
Corones Suárez, Argentina
502.373.357 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
502.373.358 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
502.373.360 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
502.373.361 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
502.373.377 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
502.373.364 Boehringer Ingelheim Investigational Site
La Plata, Argentina
502.373.365 Boehringer Ingelheim Investigational Site
Mar del Plata, Argentina
502.373.366 Boehringer Ingelheim Investigational Site
Mendoza, Argentina
502.373.376 Boehringer Ingelheim Investigational Site
Mendoza, Argentina
502.373.367 Boehringer Ingelheim Investigational Site
Rosario, Argentina
502.373.369 Boehringer Ingelheim Investigational Site
Salta, Argentina
502.373.371 Boehringer Ingelheim Investigational Site
San Miguel de Tucumán, Argentina
502.373.373 Boehringer Ingelheim Investigational Site
San Miguel de Tucumán, Argentina
502.373.375 Boehringer Ingelheim Investigational Site
Santa Fe, Argentina
502.373.374 Boehringer Ingelheim Investigational Site
Zárate, Argentina
502.373.0534 The Canberra Hospital
Woden, Australian Capital Territory, Australia
502.373.0536 Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
502.373.0544 Coffs Harbour Cardiovascular Clinic
Coffs Harbour, New South Wales, Australia
502.373.0538 Concord Repatriation General Hospital
Concord, New South Wales, Australia
502.373.0539 Central Coast Neuroscience Research
Gosford, New South Wales, Australia
502.373.0556 Gosford Hospital
Gosford, New South Wales, Australia
502.373.0542 St. George Hospital
Kogarah, New South Wales, Australia
502.373.0552 St George Private Hospital
Kogarah, New South Wales, Australia
502.373.0559 St George Hospital - Dept of Clinical Pharmacology
Kogarah, New South Wales, Australia
502.373.0528 John Hunter Hospital
Newcastle, New South Wales, Australia
502.373.0535 The Prince of Wales Hospital
Randwick, New South Wales, Australia
502.373.0533 Royal North Shore Hospital
St Leonards, New South Wales, Australia
502.373.0549 Illawarra Regional Hospital
Wollongong, New South Wales, Australia
502.373.0523 The Prince Charles Hospital
Chermside, Queensland, Australia
502.373.0524 Royal Brisbane Hospital
Herston, Queensland, Australia
502.373.0526 Peninsula Clinical Research Centre
Kippa-Ring, Queensland, Australia
502.373.0540 Gold Coast Hospital
Southport, Queensland, Australia
502.373.0521 Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
502.373.0546 Flinders Medical Centre
Bedford Park, South Australia, Australia
502.373.0550 Repatriation General Hospital
Daw Park, South Australia, Australia
502.373.0551 Port Lincoln "The Investigator" Clinic
Port Lincoln, South Australia, Australia
502.373.0529 Launceston General Hospital
Launceston, Tasmania, Australia
502.373.0531 Box Hill Hospital
Box Hill, Victoria, Australia
502.373.0548 The Northern Hospital
Epping, Victoria, Australia
502.373.0522 The Geelong Hospital
Geelong, Victoria, Australia
502.373.0520 Royal Melbourne Hospital
Parkville, Victoria, Australia
502.373.0525 The Alfred Hospital
Prahran, Victoria, Australia
502.373.0532 Baker Medical Research Centre
Prahran, Victoria, Australia
502.373.0557 Maroondah Hospital
Ringwood East, Victoria, Australia
502.373.0537 Austin & Repatriation Medical Centre
West Heidelberg, Victoria, Australia
502.373.0547 Fremantle Hospital
Fremantle, Western Australia, Australia
502.373.0530 Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
502.373.0545 Royal Perth Hospital
Perth, Western Australia, Australia
502.373.1128 Boehringer Ingelheim Investigational Site
Graz, Austria
502.373.1126 Boehringer Ingelheim Investigational Site
Vienna, Austria
502.373.1127 Boehringer Ingelheim Investigational Site
Vienna, Austria
502.373.1129 Boehringer Ingelheim Investigational Site
Vienna, Austria
502.373.1125 Boehringer Ingelheim Investigational Site
Wels, Austria
502.373.1004 Boehringer Ingelheim Investigational Site
Aalst, Belgium
502.373.1015 Boehringer Ingelheim Investigational Site
Anderlecht, Belgium
502.373.1005 Boehringer Ingelheim Investigational Site
Antwerp, Belgium
502.373.1022 Boehringer Ingelheim Investigational Site
Bornem, Belgium
502.373.1021 Boehringer Ingelheim Investigational Site
Brasschaat, Belgium
502.373.1003 Boehringer Ingelheim Investigational Site
Bruges, Belgium
502.373.1017 Boehringer Ingelheim Investigational Site
Charleroi, Belgium
502.373.1009 Boehringer Ingelheim Investigational Site
Genk, Belgium
502.373.1018 Boehringer Ingelheim Investigational Site
Godinne, Belgium
502.373.1011 Boehringer Ingelheim Investigational Site
Haine-Saint-Paul, Belgium
502.373.1019 Boehringer Ingelheim Investigational Site
Haine-Saint-Paul, Belgium
502.373.1007 Boehringer Ingelheim Investigational Site
Hasselt, Belgium
502.373.1000 Boehringer Ingelheim Investigational Site
Leuven, Belgium
502.373.1020 Boehringer Ingelheim Investigational Site
Mechelen, Belgium
502.373.1006 Boehringer Ingelheim Investigational Site
Mol, Belgium
502.373.1028 Boehringer Ingelheim Investigational Site
Roeselare, Belgium
502.373.1014 Boehringer Ingelheim Investigational Site
Seraing, Belgium
502.373.1002 Boehringer Ingelheim Investigational Site
Turnhout, Belgium
502.373.1010 Boehringer Ingelheim Investigational Site
Turnhout, Belgium
502.373.1025 Boehringer Ingelheim Investigational Site
Woluwé-Saint-Lambert, Belgium
502.373.405 Boehringer Ingelheim Investigational Site
Belo Horizonte, Brazil
502.373.412 Boehringer Ingelheim Investigational Site
Belo Horizonte, Brazil
502.373.426 Boehringer Ingelheim Investigational Site
Belo Horizonte, Brazil
502.373.418 Boehringer Ingelheim Investigational Site
Botucatu, Brazil
502.373.407 Boehringer Ingelheim Investigational Site
Campinas, Brazil
502.373.419 Boehringer Ingelheim Investigational Site
Campinas, Brazil
502.373.425 Boehringer Ingelheim Investigational Site
Cerqueira César - São Paulo, Brazil
502.373.406 Boehringer Ingelheim Investigational Site
Curitiba, Brazil
502.373.411 Boehringer Ingelheim Investigational Site
Goiânia, Brazil
502.373.403 Boehringer Ingelheim Investigational Site
Marília, Brazil
502.373.400 Boehringer Ingelheim Investigational Site
Pelotas, Brazil
502.373.416 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
502.373.417 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
502.373.415 Boehringer Ingelheim Investigational Site
Porto Alegre - Rs, Brazil
502.373.420 Boehringer Ingelheim Investigational Site
Ribeirão Preto, Brazil
502.373.414 Boehringer Ingelheim Investigational Site
Rio de Janeiro, Brazil
502.373.413 Boehringer Ingelheim Investigational Site
Rio de Janeiro - Rj, Brazil
502.373.409 Boehringer Ingelheim Investigational Site
Salvador, Brazil
502.373.410 Boehringer Ingelheim Investigational Site
Salvador, Brazil
502.373.404 Boehringer Ingelheim Investigational Site
Santa Catalina, Brazil
502.373.421 Boehringer Ingelheim Investigational Site
São José do Rio Preto, Brazil
502.373.402 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
502.373.408 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
502.373.422 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
502.373.424 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
502.373.423 Boehringer Ingelheim Investigational Site
Vila Clementino, São Paulo, Brazil
502.373.0001 C849 Division of Cardiology, Foothills Medical Centre
Calgary, Alberta, Canada
502.373.0071 Peter Lougheed Centre
Calgary, Alberta, Canada
502.373.0020 CHA/University Hospital
Edmonton, Alberta, Canada
502.373.0073 Alder Medical Centre
Campbell River, British Columbia, Canada
502.373.0062 Gain Medical Centre
Coquitlam, British Columbia, Canada
502.373.0046 Interior Clinical Research Consultants Ltd
Kelowna, British Columbia, Canada
502.373.0038 New West Cardiac Research
New Westminster, British Columbia, Canada
502.373.0048 Suite 100
North Vancouver, British Columbia, Canada
502.373.0002 Penticton Regional Hospital
Penticton, British Columbia, Canada
502.373.0009 Vancouver Hospital
Vancouver, British Columbia, Canada
502.373.0003 Discovery Clinical Services Ltd
Victoria, British Columbia, Canada
502.373.0030 Portage Clinical Studies
Manitoba, Manitoba, Canada
502.373.0050 St. Pierre Medical Clinic
Saint Pierre, Manitoba, Canada
502.373.0077 Health Science Centre Diabetes Research Group
Winnipeg, Manitoba, Canada
502.373.0005 Dr. Jeffrey Hiscock
St. John's, Newfoundland and Labrador, Canada
502.373.0006 The General Hospital
St. John's, Newfoundland and Labrador, Canada
502.373.0056 Antigonish Clinical Trials
Antigonish, Nova Scotia, Canada
502.373.0045 Queen Elizabeth II HSC
Halifax, Nova Scotia, Canada
502.373.0031 Brampton Research Associates
Brampton, Ontario, Canada
502.373.0007 Sudbury Cardiac Research
Greater Sudbury, Ontario, Canada
502.373.0011 St. Joseph's Hospital Cardiac Research
Hamilton, Ontario, Canada
502.373.0034 HGH McMaster Clinic
Hamilton, Ontario, Canada
502.373.0035 Hamilton Medical Research
Hamilton, Ontario, Canada
502.373.0064 Chedoke Hospital
Hamilton, Ontario, Canada
502.373.0082 3U4, McMaster University Medical Centre
Hamilton, Ontario, Canada
502.373.0085 HGH McMaster Clinic
Hamilton, Ontario, Canada
502.373.0024 London HSC - University Hospital
London, Ontario, Canada
502.373.0044 Mississauga Clinical Research Centre
Mississauga, Ontario, Canada
502.373.0043 Fraser Clinical Trial Inc
New Westminster, Ontario, Canada
502.373.0032 New Market Cardiology Research Grp
Newmarket, Ontario, Canada
502.373.0037 Niagara Falls Medical Centre
Niagara Falls, Ontario, Canada
502.373.0054 Orleans Medical-Dental Centre
Orléans, Ontario, Canada
502.373.0058 Medical Sciences Building
Oshawa, Ontario, Canada
502.373.0063 Paradigm Clinical Trials
Oshawa, Ontario, Canada
502.373.0029 Riverside Professional Building
Ottawa, Ontario, Canada
502.373.0051 Merivale Cardiovascular Consultants
Ottawa, Ontario, Canada
502.373.0040 Etobicok Cardiology
Rexdale, Ontario, Canada
502.373.0023 Group Health Centre - Clinical Trials
Sault Ste. Marie, Ontario, Canada
502.373.0039 Scarborough Cardiology Research
Scarborough Village, Ontario, Canada
502.373.0061 CLIKS Medical Research Corp
Thunder Bay, Ontario, Canada
502.373.0042 Sunnybrook & Woman's College Health Science Centre
Toronto, Ontario, Canada
502.373.0083 St. Michael's Hospital
Toronto, Ontario, Canada
502.373.0052 Dr. Bruce Lubelsky
Willowdale, Ontario, Canada
502.373.0008 Windsor Health Clinic
Windsor, Ontario, Canada
502.373.0081 Centre de recherche clinique, CUSE 3001
Fleurimont, Quebec, Canada
502.373.0076 Centre Hospitalier de Vallees de l'Outaouais Gatineau
Gatineau, Quebec, Canada
502.373.0057 Centre De Recherche Clinique
Laval, Quebec, Canada
502.373.0033 Clinique de Cardiologie de Levis
Lévis, Quebec, Canada
502.373.0010 Recherche Invascor
Longueuil, Quebec, Canada
502.373.0013 Suite 170
Longueuil, Quebec, Canada
502.373.0014 Via Car Recherche Clinique Inc
Longueuil, Quebec, Canada
502.373.0015 C/O Peter Carmichael
Longueuil, Quebec, Canada
502.373.0016 Suite 170
Longueuil, Quebec, Canada
502.373.0017 Suite 170
Longueuil, Quebec, Canada
502.373.0086 Via Car Recherche Clinique Inc
Longueuil, Quebec, Canada
502.373.0018 Montreal Heart Institute
Montreal, Quebec, Canada
502.373.0021 Medi - recherche Inc.
Montreal, Quebec, Canada
502.373.0022 CHUM - Hotel Dieu
Montreal, Quebec, Canada
502.373.0025 Hopital Maisonneuve Rosemont
Montreal, Quebec, Canada
502.373.0079 Jewish General Hospital
Montreal, Quebec, Canada
502.373.0028 Hop. Du St. Sacrement
Québec, Quebec, Canada
502.373.0041 Recherches Clinicar Inc.
Québec, Quebec, Canada
502.373.0080 Polyclinique vasculaire Centre hospitalier universitaire de
Québec, Quebec, Canada
502.373.0084 CHA-Hopital de l'Efant-Jesus
Québec, Quebec, Canada
502.373.0027 Ctr Hospitalier Beauce Etchemin
Saint George de Beauce, Quebec, Canada
502.373.0012 Hopital Laval - Institute Cardiologie de Quebec
Ste-Foy, Quebec, Canada
502.373.0026 Centre hospitalier Pierre-Le Gardeur
Terrebonne, Quebec, Canada
502.373.0072 Chra
Thetford-Mines, Quebec, Canada
502.373.0053 Mount Royal Clinic
Saskatoon, Saskatchewan, Canada
502.373.0055 Specialists - Internal Medicine
Saskatoon, Saskatchewan, Canada
502.373.0066 SDRI - University of Saskatchewan
Saskatoon, Saskatchewan, Canada
502.373.0067 SDRI - University of Saskatchewan
Saskatoon, Saskatchewan, Canada
502.373.0068 SDRI - University of Saskatchewan
Saskatoon, Saskatchewan, Canada
502.373.0070 SDRI - University of Saskatchewan
Saskatoon, Saskatchewan, Canada
502.373.0601 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0602 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0603 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0604 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0605 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0606 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0607 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0621 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0622 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0623 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0626 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0616 Boehringer Ingelheim Investigational Site
Changsha, China
502.373.0613 Boehringer Ingelheim Investigational Site
Chengdu, China
502.373.0625 Boehringer Ingelheim Investigational Site
Chengdu, China
502.373.0620 Boehringer Ingelheim Investigational Site
Guangzhou, China
502.373.0612 Boehringer Ingelheim Investigational Site
Harbin, China
502.373.0634 Boehringer Ingelheim Investigational Site
HeBei Province, China
502.373.0624 Boehringer Ingelheim Investigational Site
Henan Province, China
502.373.0627 Boehringer Ingelheim Investigational Site
Hubei Province, China
502.373.0614 Boehringer Ingelheim Investigational Site
Nanjing, China
502.373.0629 Boehringer Ingelheim Investigational Site
Qingdao, China
502.373.0632 Boehringer Ingelheim Investigational Site
ShanDong Province, China
502.373.0633 Boehringer Ingelheim Investigational Site
ShanDong Province, China
502.373.0617 Boehringer Ingelheim Investigational Site
Shanghai, China
502.373.0618 Boehringer Ingelheim Investigational Site
Shanghai, China
502.373.0619 Boehringer Ingelheim Investigational Site
Shanghai, China
502.373.0628 Boehringer Ingelheim Investigational Site
Shenyang, China
502.373.0611 Boehringer Ingelheim Investigational Site
Shijiazhuang, China
502.373.0615 Boehringer Ingelheim Investigational Site
Tianjin, China
502.373.0631 Boehringer Ingelheim Investigational Site
Tianjin, China
502.373.0630 Boehringer Ingelheim Investigational Site
Weizikeng, China
502.373.0608 Boehringer Ingelheim Investigational Site
Wuhan, China
502.373.0610 Boehringer Ingelheim Investigational Site
Zhenzhou, China
502.373.1053 Boehringer Ingelheim Investigational Site
Brno, Czechia
502.373.1060 Boehringer Ingelheim Investigational Site
Havířov, Czechia
502.373.1055 Boehringer Ingelheim Investigational Site
Kladno, Czechia
502.373.1059 Boehringer Ingelheim Investigational Site
Mladá Boleslav, Czechia
502.373.1061 Boehringer Ingelheim Investigational Site
Pilsen, Czechia
502.373.1051 Boehringer Ingelheim Investigational Site
Prague, Czechia
502.373.1057 Boehringer Ingelheim Investigational Site
Prague, Czechia
502.373.1062 Boehringer Ingelheim Investigational Site
Prague, Czechia
502.373.1056 Boehringer Ingelheim Investigational Site
Příbram, Czechia
502.373.1058 Boehringer Ingelheim Investigational Site
Ústí nad Orlicí, Czechia
502.373.1450 Boehringer Ingelheim Investigational Site
Aalborg, Denmark
502.373.1453 Boehringer Ingelheim Investigational Site
Aarhus C, Denmark
502.373.1460 Boehringer Ingelheim Investigational Site
Elsinore, Denmark
502.373.1455 Boehringer Ingelheim Investigational Site
Frederiksberg, Denmark
502.373.1459 Boehringer Ingelheim Investigational Site
Frederiksberg C, Denmark
502.373.1458 Boehringer Ingelheim Investigational Site
Hilleroed, Denmark
502.373.1451 Boehringer Ingelheim Investigational Site
Holbæk, Denmark
502.373.1452 Boehringer Ingelheim Investigational Site
Hvidovre, Denmark
502.373.1461 Boehringer Ingelheim Investigational Site
Kjellerup, Denmark
502.373.1456 Boehringer Ingelheim Investigational Site
Randers, Denmark
502.373.1457 Boehringer Ingelheim Investigational Site
Slagelse, Denmark
502.373.1454 Boehringer Ingelheim Investigational Site
Svendborg, Denmark
502.373.1486 Boehringer Ingelheim Investigational Site
Hämeenlinna, Finland
502.373.1470 Boehringer Ingelheim Investigational Site
Helsinki, Finland
502.373.1473 Boehringer Ingelheim Investigational Site
Helsinki, Finland
502.373.1479 Boehringer Ingelheim Investigational Site
Jyväskylä, Finland
502.373.1488 Boehringer Ingelheim Investigational Site
Kuopio, Finland
502.373.1481 Boehringer Ingelheim Investigational Site
Kuusankoski, Finland
502.373.1487 Boehringer Ingelheim Investigational Site
Liperi, Finland
502.373.1475 Boehringer Ingelheim Investigational Site
Oulun Kaupunki, Finland
502.373.1471 Boehringer Ingelheim Investigational Site
Turku, Finland
502.373.1485 Boehringer Ingelheim Investigational Site
Vantaa, Finland
502.373.1093 Cabinet Médical
Albens, France
502.373.1090 Cabinet Médical
Béziers, France
502.373.1075 Cabinet Médical
Bourges, France
502.373.1091 Cabinet Médical
Broglie, France
502.373.1097 Cabinet Médical
Castelnaudary, France
502.373.1089 Cabinet Médical
Gémenos, France
502.373.1099 Cabinet Médical
Husseren Wesserlin, France
502.373.1094 Cabinet Médical
Hyères, France
502.373.1078 Cabinet Médical des Tanneurs
L'Aigle, France
502.373.1096 Cabinet Médical
La Rochelle, France
502.373.1081 Cabinet Médical
Le Pradet, France
502.373.1083 Cabinet Médical
Mûrs-Erigné, France
502.373.1084 Cabinet Médical
Nantes, France
502.373.1086 Cabinet Médical
Nantes, France
502.373.1080 Cabinet Médical
Niort, France
502.373.1095 Cabinet Médical
Orthez, France
502.373.1079 Cabinet Médical
Paris, France
502.373.1088 Cabinet Médical
Rennes, France
502.373.1098 Cabinet Médical
Rosiers-d'Égletons, France
502.373.1076 Cabinet Médical La Grande Ramée
Saint Martin dHyeres, France
502.373.1085 Cabinet Médical
Saint-Julien-des-Landes, France
502.373.1092 Cabinet Médical de St Pierre
Saint-Pierre-de-Chandieu, France
502.373.1077 Cabinet Médical
Saint-Romain-sur-Cher, France
502.373.1087 Cabinet Médical
Strasbourg, France
502.373.1082 Cabinet Médical
Tours, France
502.373.1164 Boehringer Ingelheim Investigational Site
Bad Lausick, Germany
502.373.1166 Boehringer Ingelheim Investigational Site
Bad Lauterberg im Harz, Germany
502.373.1138 Boehringer Ingelheim Investigational Site
Bad Mergentheim, Germany
502.373.1156 Boehringer Ingelheim Investigational Site
Berlin, Germany
502.373.1160 Boehringer Ingelheim Investigational Site
Berlin, Germany
502.373.1161 Boehringer Ingelheim Investigational Site
Berlin, Germany
502.373.1144 Boehringer Ingelheim Investigational Site
Bielefeld, Germany
502.373.1137 Boehringer Ingelheim Investigational Site
Cologne, Germany
502.373.1152 Boehringer Ingelheim Investigational Site
Dessau, Germany
502.373.1139 Boehringer Ingelheim Investigational Site
Dortmund, Germany
502.373.1159 Boehringer Ingelheim Investigational Site
Dortmund, Germany
502.373.1136 Boehringer Ingelheim Investigational Site
Dresden, Germany
502.373.1145 Boehringer Ingelheim Investigational Site
Eberswalde, Germany
502.373.1155 Boehringer Ingelheim Investigational Site
Erlangen, Germany
502.373.1157 Boehringer Ingelheim Investigational Site
Essen, Germany
502.373.1153 Boehringer Ingelheim Investigational Site
Haag, Germany
502.373.1148 Boehringer Ingelheim Investigational Site
Hamburg, Germany
502.373.1132 Boehringer Ingelheim Investigational Site
Heidelberg, Germany
502.373.1131 Boehringer Ingelheim Investigational Site
Homburg/Saar, Germany
502.373.1147 Boehringer Ingelheim Investigational Site
Karlsburg, Germany
502.373.1154 Boehringer Ingelheim Investigational Site
Kelkheim, Germany
502.373.1142 Boehringer Ingelheim Investigational Site
Künzing, Germany
502.373.1165 Boehringer Ingelheim Investigational Site
Lübeck, Germany
502.373.1134 Boehringer Ingelheim Investigational Site
Mainz, Germany
502.373.1133 Boehringer Ingelheim Investigational Site
Melsungen, Germany
502.373.1146 Boehringer Ingelheim Investigational Site
München, Germany
502.373.1149 Boehringer Ingelheim Investigational Site
Offenbach, Germany
502.373.1162 Boehringer Ingelheim Investigational Site
Riesa, Germany
502.373.1140 Boehringer Ingelheim Investigational Site
Rostock, Germany
502.373.1150 Boehringer Ingelheim Investigational Site
Sindelfingen, Germany
502.373.1163 Boehringer Ingelheim Investigational Site
Starnberg, Germany
502.373.1158 Boehringer Ingelheim Investigational Site
Stuttgart, Germany
502.373.1167 Boehringer Ingelheim Investigational Site
Timmendorfer Strand, Germany
502.373.1135 Boehringer Ingelheim Investigational Site
Wiesbaden, Germany
502.373.1141 Boehringer Ingelheim Investigational Site
Witten, Germany
502.373.1200 Boehringer Ingelheim Investigational Site
Athens, Greece
502.373.1203 Boehringer Ingelheim Investigational Site
Athens, Greece
502.373.1206 Boehringer Ingelheim Investigational Site
Athens, Greece
502.373.1207 Boehringer Ingelheim Investigational Site
Athens, Greece
502.373.1208 Boehringer Ingelheim Investigational Site
Athens, Greece
502.373.1214 Boehringer Ingelheim Investigational Site
Athens, Greece
502.373.1224 Boehringer Ingelheim Investigational Site
Corinth, Greece
502.373.1209 Boehringer Ingelheim Investigational Site
Elefsina, Greece
502.373.1211 Boehringer Ingelheim Investigational Site
Goudi/ Athens, Greece
502.373.1201 Boehringer Ingelheim Investigational Site
Ioannina, Greece
502.373.1210 Boehringer Ingelheim Investigational Site
Kavala,greece, Greece
502.373.1202 Boehringer Ingelheim Investigational Site
Melissia, Athens, Greece
502.373.1205 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
502.373.1213 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
502.373.1204 Boehringer Ingelheim Investigational Site
Véria, Greece
502.373.0676 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
502.373.0677 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
502.373.0680 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
502.373.0681 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
502.373.0685 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
502.373.1227 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1230 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1231 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1232 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1233 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1235 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1237 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1239 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1242 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1244 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1236 Boehringer Ingelheim Investigational Site
Debrecen, Hungary
502.373.1240 Boehringer Ingelheim Investigational Site
Debrecen, Hungary
502.373.1228 Boehringer Ingelheim Investigational Site
Kecskemét, Hungary
502.373.1241 Boehringer Ingelheim Investigational Site
Nyíregyháza, Hungary
502.373.1226 Boehringer Ingelheim Investigational Site
Pécs, Hungary
502.373.1229 Boehringer Ingelheim Investigational Site
Siófok, Hungary
502.373.1238 Boehringer Ingelheim Investigational Site
Szeged, Hungary
502.373.1225 Boehringer Ingelheim Investigational Site
Székesfehérvár, Hungary
502.373.1234 Boehringer Ingelheim Investigational Site
Tatabánya, Hungary
502.373.1243 Boehringer Ingelheim Investigational Site
Veszprém, Hungary
502.373.1714 Dept. of Clinical Pharmacology
Dublin, Ireland
502.373.1717 Adelaide & Meath Hospitals
Dublin, Ireland
502.373.1719 Pulmonary Function Laboratory
Dublin, Ireland
502.373.1720 Mallow General Hospital
Mallow, Ireland
502.373.1257 Ospedale "Mazzoni"
Ascoli Piceno, Italy
502.373.1259 Ospedale di Bentivoglio
Bentivoglio (BO), Italy
502.373.1255 Ospedale "S. Orsola Malpighi"
Bologna, Italy
502.373.1278 Ospedale Bellaria
Bologna, Italy
502.373.1275 A.O. Spedali Civili di Brescia -Univ. degli studi di Brescia
Brescia, Italy
502.373.1261 Ospedale Civile di Casarano
Casarano (LE), Italy
502.373.1252 Azienda Ospedaliera di Caserta
Caserta, Italy
502.373.1254 Ospedale di Città della Pieve
Città Della Pieve (PG), Italy
502.373.1262 Arcispedale "S. Anna"
Ferrara, Italy
502.373.1250 Ospedale Civile "S. Polo"
Monfalcone (go), Italy
502.373.1266 Azienda Universitaria Policlinico "Federico II"
Napoli, Italy
502.373.1267 Azienda Universitaria Policlinico II
Napoli, Italy
502.373.1269 Università Federico II
Napoli, Italy
502.373.1279 Asl Na 1
Napoli, Italy
502.373.1264 Presidio Ospedaliero "Villa Sofia"
Palermo, Italy
502.373.1265 IRCCS - Policlinico S. Matteo
Pavia, Italy
502.373.1251 Policlinico Monteluce
Perugia, Italy
502.373.1258 Ospedale "R. Silvestrini"
Perugia, Italy
502.373.1274 Ospedale "R. Silvestrini"
Perugia, Italy
502.373.1253 Istituto di Ricovero a Carattere Scientifico Neuromed- IRCCS
Pozzilli (IS), Italy
502.373.1263 Policlinico Umberto I
Roma, Italy
502.373.1268 Ospedale "S. Spirito"
Roma, Italy
502.373.1270 Policlinico di Tor Vergata
Roma, Italy
502.373.1273 A.O. "S. Camillo de Lellis"
Roma, Italy
502.373.1260 Ospedale "N. Melli"
S. Pietro Vernotico (BR), Italy
502.373.1256 Ospedale Civile SS. Annunziata - USL 1
Sassari, Italy
502.373.1277 A.S.O. "S. Giovanni Battista"
Torino, Italy
502.373.1272 Ospedale di Circolo di Varese
Varese, Italy
502.373.1271 Ospedale Civile
Venezia, Italy
502.373.1276 Ospedale Belcolle
Viterbo, Italy
502.373.0733 Boehringer Ingelheim Investigational Site
George Town, Malaysia
502.373.0736 Boehringer Ingelheim Investigational Site
Johor Bahru, Malaysia
502.373.2707 Boehringer Ingelheim Investigational Site
Kelantan Darul Naim, Malaysia
502.373.0739 Boehringer Ingelheim Investigational Site
Kelantan, Malaysia
502.373.0732 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
502.373.0734 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
502.373.60001 Boehringer Ingelheim Investigational Site
Kuala Selangor, Malaysia
502.373.0731 Boehringer Ingelheim Investigational Site
Putrajaya, Malaysia
502.373.0450 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
502.373.0451 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
502.373.0452 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
502.373.0459 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
502.373.0460 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
502.373.0461 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
502.373.0470 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
502.373.0457 Boehringer Ingelheim Investigational Site
México, Mexico
502.373.0458 Boehringer Ingelheim Investigational Site
México, Mexico
502.373.0454 Boehringer Ingelheim Investigational Site
Monterrey, Mexico
502.373.0453 Boehringer Ingelheim Investigational Site
Zapopan, Mexico
502.373.0456 Boehringer Ingelheim Investigational Site
Zapopan, Mexico
502.373.1313 Boehringer Ingelheim Investigational Site
's-Hertogenbosch, Netherlands
502.373.1309 Boehringer Ingelheim Investigational Site
Amsterdam, Netherlands
502.373.1305 Boehringer Ingelheim Investigational Site
Beverwijk, Netherlands
502.373.1302 Boehringer Ingelheim Investigational Site
Doetinchem, Netherlands
502.373.1304 Boehringer Ingelheim Investigational Site
Drachten, Netherlands
502.373.1301 Boehringer Ingelheim Investigational Site
Eindhoven, Netherlands
502.373.1318 Boehringer Ingelheim Investigational Site
Ermelo, Netherlands
502.373.1320 Boehringer Ingelheim Investigational Site
Ewijk, Netherlands
502.373.1310 Boehringer Ingelheim Investigational Site
Hengelo, Netherlands
502.373.1303 Boehringer Ingelheim Investigational Site
Hoorn, Netherlands
502.373.1322 Boehringer Ingelheim Investigational Site
Huizen, Netherlands
502.373.1300 Boehringer Ingelheim Investigational Site
Lichtenvoorde, Netherlands
502.373.1323 Boehringer Ingelheim Investigational Site
Losser, Netherlands
502.373.1307 Boehringer Ingelheim Investigational Site
Nieuwegein, Netherlands
502.373.1317 Boehringer Ingelheim Investigational Site
Rijswijk, Netherlands
502.373.1319 Boehringer Ingelheim Investigational Site
Roelofarendsveen, Netherlands
502.373.1308 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
502.373.1321 Boehringer Ingelheim Investigational Site
Spijkenisse, Netherlands
502.373.1311 Boehringer Ingelheim Investigational Site
Stadskanaal, Netherlands
502.373.1312 Boehringer Ingelheim Investigational Site
The Hague, Netherlands
502.373.1314 Boehringer Ingelheim Investigational Site
Tilburg, Netherlands
502.373.1316 Boehringer Ingelheim Investigational Site
Utrecht, Netherlands
502.373.1315 Boehringer Ingelheim Investigational Site
Velp, Netherlands
502.373.0500 Boehringer Ingelheim Investigational Site
Auckland, New Zealand
502.373.0502 Boehringer Ingelheim Investigational Site
Auckland, New Zealand
502.373.0507 Boehringer Ingelheim Investigational Site
Christchurch, New Zealand
502.373.0504 Boehringer Ingelheim Investigational Site
Hamiton, New Zealand
502.373.0506 Boehringer Ingelheim Investigational Site
Hasting, New Zealand
502.373.0501 Middlemore Hospital
Otahuhu Auckland, New Zealand
502.373.0503 Boehringer Ingelheim Investigational Site
Takapuna Auckland, New Zealand
502.373.0505 Tauranga Study Centre
Tauranga, New Zealand
502.373.20003 Boehringer Ingelheim Investigational Site
Fevik, Norway
502.373.20004 Fana Hjertesenter
Nesttun, Norway
502.373.20001 Stavanger Universitetssykehus
Stavanger, Norway
502.373.20002 Tvedestrand Legesenter
Tvedestrand, Norway
502.373.20005 Sykehuset i Vestfold, Avd. Tønsberg
Tønsberg, Norway
502.373.0702 De La Salle University Medical Center
Cavite, Philippines
502.373.0700 Philippine General Hospital
Manila, Philippines
502.373.0701 Manila Doctors Hospital, Room 3 Annex
Manila, Philippines
502.373.0705 The Medical City
Pasig, Philippines
502.373.0703 Philippine Heart Center
Quezon City, Philippines
502.373.0704 National Kidney & Transplant Institute, Room 821
Quezon City, Philippines
502.373.1354 Boehringer Ingelheim Investigational Site
Bydgoszcz, Poland
502.373.1366 Boehringer Ingelheim Investigational Site
Częstochowa, Poland
502.373.1368 Boehringer Ingelheim Investigational Site
Gdynia, Poland
502.373.1365 Boehringer Ingelheim Investigational Site
Gdynia Redlowo, Poland
502.373.1359 Boehringer Ingelheim Investigational Site
Grójec, Poland
502.373.1369 Boehringer Ingelheim Investigational Site
Grudziądz, Poland
502.373.1375 Boehringer Ingelheim Investigational Site
Inowrocław, Poland
502.373.1360 Boehringer Ingelheim Investigational Site
Jarosławiec, Poland
502.373.1372 Boehringer Ingelheim Investigational Site
Katowice, Poland
502.373.1376 Boehringer Ingelheim Investigational Site
Katowice, Poland
502.373.1361 Boehringer Ingelheim Investigational Site
Kielce, Poland
502.373.1358 Boehringer Ingelheim Investigational Site
Lodz, Poland
502.373.1364 Boehringer Ingelheim Investigational Site
Lubartów, Poland
502.373.1374 Boehringer Ingelheim Investigational Site
Lubin, Poland
502.373.1367 Boehringer Ingelheim Investigational Site
Nowy Sącz, Poland
502.373.1356 Boehringer Ingelheim Investigational Site
Piotrkow Trybunalski, Poland
502.373.1370 Boehringer Ingelheim Investigational Site
Poznan, Poland
502.373.1357 Boehringer Ingelheim Investigational Site
Ruda Śląska, Poland
502.373.1352 Boehringer Ingelheim Investigational Site
Skierniewice, Poland
502.373.1362 Boehringer Ingelheim Investigational Site
Tarnów, Poland
502.373.1355 Boehringer Ingelheim Investigational Site
Tomaszów Mazowiecki, Poland
502.373.1353 Boehringer Ingelheim Investigational Site
Torun, Poland
502.373.1351 Boehringer Ingelheim Investigational Site
Warsaw, Poland
502.373.1363 Boehringer Ingelheim Investigational Site
Warsaw, Poland
502.373.1373 Boehringer Ingelheim Investigational Site
Węgrów, Poland
502.373.1402 Hospital Garcia de Orta
Almada, Portugal
502.373.1400 Hospital Fernando Fonseca
Amadora, Portugal
502.373.1411 Hospital de Santa Cruz
Carnaxide, 2799-523, Portugal
502.373.1408 Hospitais da Universidade de Coimbra
Coimbra, Portugal
502.373.1406 Hospital Distrital de Faro Geral
Faro, Portugal
502.373.1403 Hospital de Santa Marta
Lisbon, Portugal
502.373.1409 Hospital de Santa Maria
Lisbon, Portugal
502.373.1401 Unidade Local de Saúde de Matosinhos
Matosinhos Municipality, Portugal
502.373.1410 Hospital de Santo António
Porto, Portugal
502.373.1407 Centro Hospitalar vila Nova de Gaia
Vila Nova de Gaia, Portugal
502.373.0215 Boehringer Ingelheim Investigational Site
Caguas, Puerto Rico
502.373.0267 Boehringer Ingelheim Investigational Site
Las Lomas, Puerto Rico
502.373.0190 Boehringer Ingelheim Investigational Site
Manatí, Puerto Rico
502.373.0198 Boehringer Ingelheim Investigational Site
Orocovis, Puerto Rico
502.373.0262 Boehringer Ingelheim Investigational Site
Rio Piedras, Puerto Rico
502.373.1425 Boehringer Ingelheim Investigational Site
Moscow, Russia
502.373.1426 Boehringer Ingelheim Investigational Site
Moscow, Russia
502.373.1427 Boehringer Ingelheim Investigational Site
Moscow, Russia
502.373.1428 Boehringer Ingelheim Investigational Site
Moscow, Russia
502.373.1429 Boehringer Ingelheim Investigational Site
Moscow, Russia
502.373.1430 Boehringer Ingelheim Investigational Site
Moscow, Russia
502.373.1433 Boehringer Ingelheim Investigational Site
Moscow, Russia
502.373.1431 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russia
502.373.1432 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russia
502.373.2706 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Singapore
502.373.0725 Boehringer Ingelheim Investigational Site
Singapore, Singapore
502.373.0726 Boehringer Ingelheim Investigational Site
Singapore, Singapore
502.373.1535 Boehringer Ingelheim Investigational Site
Bratislava, Slovakia
502.373.1529 Boehringer Ingelheim Investigational Site
Košice, Slovakia
502.373.1540 Boehringer Ingelheim Investigational Site
Košice, Slovakia
502.373.1538 Boehringer Ingelheim Investigational Site
Nitra, Slovakia
502.373.1545 Boehringer Ingelheim Investigational Site
Rimavská Sobota, Slovakia
502.373.1553 Boehringer Ingelheim Investigational Site
Bellville, South Africa
502.373.1552 Boehringer Ingelheim Investigational Site
Bloemfontein, South Africa
502.373.1550 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
502.373.1561 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
502.373.1551 Boehringer Ingelheim Investigational Site
Durban, South Africa
502.373.1560 Boehringer Ingelheim Investigational Site
Fiachrdtpark, Bloemfontein, South Africa
502.373.1563 Boehringer Ingelheim Investigational Site
George East, South Africa
502.373.1554 Boehringer Ingelheim Investigational Site
KwaKhangela, South Africa
502.373.1555 Boehringer Ingelheim Investigational Site
Park Town West, South Africa
502.373.1559 Boehringer Ingelheim Investigational Site
Port Elizabeth, South Africa
502.373.1562 Boehringer Ingelheim Investigational Site
Port Elizabeth, South Africa
502.373.1558 Boehringer Ingelheim Investigational Site
Soweto, South Africa
502.373.1557 Boehringer Ingelheim Investigational Site
Sunninghill, South Africa
502.373.1564 Boehringer Ingelheim Investigational Site
Sunninghill, South Africa
502.373.1556 Boehringer Ingelheim Investigational Site
Vanderbijlpark, South Africa
502.373.0763 Boehringer Ingelheim Investigational Site
Incheon, South Korea
502.373.0764 Boehringer Ingelheim Investigational Site
Kwangju, South Korea
502.373.0755 Boehringer Ingelheim Investigational Site
Pusan, South Korea
502.373.0750 Boehringer Ingelheim Investigational Site
Seoul, South Korea
502.373.0753 Boehringer Ingelheim Investigational Site
Seoul, South Korea
502.373.0756 Boehringer Ingelheim Investigational Site
Seoul, South Korea
502.373.0757 Boehringer Ingelheim Investigational Site
Seoul, South Korea
502.373.0760 Boehringer Ingelheim Investigational Site
Seoul, South Korea
502.373.0761 Boehringer Ingelheim Investigational Site
Seoul, South Korea
502.373.0754 Boehringer Ingelheim Investigational Site
Taegu, South Korea
502.373.1582 Boehringer Ingelheim Investigational Site
Alcorcón (Madrid), Spain
502.373.1601 Boehringer Ingelheim Investigational Site
Alicante, Spain
502.373.1586 Boehringer Ingelheim Investigational Site
Barcelona, Spain
502.373.1590 Boehringer Ingelheim Investigational Site
Barcelona, Spain
502.373.1597 Boehringer Ingelheim Investigational Site
Barcelona, Spain
502.373.1599 Boehringer Ingelheim Investigational Site
Barcelona, Spain
502.373.1595 Boehringer Ingelheim Investigational Site
Burjasot (Valencia), Spain
502.373.1584 Boehringer Ingelheim Investigational Site
Granada, Spain
502.373.1585 Boehringer Ingelheim Investigational Site
Granada, Spain
502.373.1576 Boehringer Ingelheim Investigational Site
Madrid, Spain
502.373.1578 Boehringer Ingelheim Investigational Site
Madrid, Spain
502.373.1580 Boehringer Ingelheim Investigational Site
Madrid, Spain
502.373.1589 Boehringer Ingelheim Investigational Site
Madrid, Spain
502.373.1592 Boehringer Ingelheim Investigational Site
Madrid, Spain
502.373.1577 Boehringer Ingelheim Investigational Site
Málaga, Spain
502.373.1596 Boehringer Ingelheim Investigational Site
Málaga, Spain
502.373.1594 Boehringer Ingelheim Investigational Site
Murcia, Spain
502.373.1579 Boehringer Ingelheim Investigational Site
Santiago de Compostela, Spain
502.373.1593 Boehringer Ingelheim Investigational Site
Santiago de Compostela, Spain
502.373.1598 Boehringer Ingelheim Investigational Site
Santiago de Compostela, Spain
502.373.1583 Boehringer Ingelheim Investigational Site
Seville, Spain
502.373.1575 Boehringer Ingelheim Investigational Site
Valencia, Spain
502.373.1591 Boehringer Ingelheim Investigational Site
Valencia, Spain
502.373.1504 Capio Lundby sjukhus
Gothenburg, Sweden
502.373.1509 Hjärtsektionen / Med.kliniken
Gothenburg, Sweden
502.373.1514 Hjärt/Kärlforskn.enheten
Gothenburg, Sweden
502.373.1501 Hjaertmottagningen
Helsingborg, Sweden
502.373.1505 Jakobsbergs sjukhus
Järfälla, Sweden
502.373.1502 Borgmästargaardens Läkarmottagning
Malmo, Sweden
502.373.1506 Hjärtmottagningen
Malmo, Sweden
502.373.1507 Kardiologiska kliniken
Malmo, Sweden
502.373.1508 Kolgahuset Läkargrupp
Malmo, Sweden
502.373.1511 Sjuntorps Vaardcentral
Sjuntorp, Sweden
502.373.1503 Källtorps Vaardcentral
Trollhättan, Sweden
502.373.1512 Vännäs Vaardcentral
Vännäs, Sweden
502.373.1625 Boehringer Ingelheim Investigational Site
Basel, Switzerland
502.373.1632 Boehringer Ingelheim Investigational Site
Bellinzona, Switzerland
502.373.1634 Boehringer Ingelheim Investigational Site
Bern, Switzerland
502.373.1627 Boehringer Ingelheim Investigational Site
Biel/Bienne, Switzerland
502.373.1631 Boehringer Ingelheim Investigational Site
Chur, Switzerland
502.373.1633 Boehringer Ingelheim Investigational Site
Kreuzlingen, Switzerland
502.373.1639 Boehringer Ingelheim Investigational Site
Lausanne, Switzerland
502.373.1629 Boehringer Ingelheim Investigational Site
Lugano, Switzerland
502.373.1628 Boehringer Ingelheim Investigational Site
Sankt Gallen, Switzerland
502.373.1637 Boehringer Ingelheim Investigational Site
Zurich, Switzerland
502.373.0780 Boehringer Ingelheim Investigational Site
Changhua, Taiwan
502.373.0779 Boehringer Ingelheim Investigational Site
Chiayi City, Taiwan
502.373.0783 Boehringer Ingelheim Investigational Site
Hualien City, Taiwan
502.373.0776 Boehringer Ingelheim Investigational Site
Kaohsiung City, Taiwan
502.373.0778 Boehringer Ingelheim Investigational Site
Kaohsiung City, Taiwan
502.373.0775 Boehringer Ingelheim Investigational Site
Tainan, Taiwan
502.373.0777 Boehringer Ingelheim Investigational Site
Tainan, Taiwan
502.373.0781 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
502.373.0782 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
502.373.0801 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
502.373.0802 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
502.373.0804 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
502.373.0805 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
502.373.0806 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
502.373.0808 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
502.373.0803 Boehringer Ingelheim Investigational Site
Khon Kaen, Thailand
502.373.0807 Boehringer Ingelheim Investigational Site
Nonthaburi, Thailand
502.373.1651 Cukurova Universitesi Tip Fakultesi
Adana, Turkey (Türkiye)
502.373.1652 Cukurova Universitesi Tip Fakultesi
Adana, Turkey (Türkiye)
502.373.1653 Ankara Hastanesi Endokrinoloji Bölümü
Ankara, Turkey (Türkiye)
502.373.1656 Baskent Universitesi Tip Fakultesi
Ankara, Turkey (Türkiye)
502.373.1659 Ankara Universitesi Tip Fakultesi
Ankara, Turkey (Türkiye)
502.373.1654 Göztepe SSK Egitim ve Arastirma Hastanesi
Istanbul, Turkey (Türkiye)
502.373.1655 Cerrahpasa Universitesi Tip Fakultesi
Istanbul, Turkey (Türkiye)
502.373.1657 Haseki Hastanesi
Istanbul, Turkey (Türkiye)
502.373.1658 Ege Universitesi Tip Fakultesi
Izmir, Turkey (Türkiye)
502.373.1650 Erciyes Universitesi Tip Fakultesi Kardiyoloji Anabilim Dali
Kayseri, Turkey (Türkiye)
502.373.1730 Boehringer Ingelheim Investigational Site
Dnyepropetrovsk, Ukraine
502.373.1731 Boehringer Ingelheim Investigational Site
Dnyepropetrovsk, Ukraine
502.373.1728 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
502.373.1732 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
502.373.1733 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
502.373.1725 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
502.373.1726 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
502.373.1727 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
502.373.1729 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
502.373.1734 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
502.373.1680 Boehringer Ingelheim Investigational Site
Abu Dhabi, United Arab Emirates
502.373.1675 Boehringer Ingelheim Investigational Site
Dubai, United Arab Emirates
502.373.1679 Boehringer Ingelheim Investigational Site
Dubai, United Arab Emirates
502.373.1677 Boehringer Ingelheim Investigational Site
Sharjah city, United Arab Emirates
502.373.1698 Boehringer Ingelheim Investigational Site
Aberdeen, United Kingdom
502.373.1706 Boehringer Ingelheim Investigational Site
Bathampton, United Kingdom
502.373.1690 Boehringer Ingelheim Investigational Site
Belfast, United Kingdom
502.373.1694 Boehringer Ingelheim Investigational Site
Birmingham, United Kingdom
502.373.1707 Boehringer Ingelheim Investigational Site
Brighton, United Kingdom
502.373.1703 Boehringer Ingelheim Investigational Site
Cardiff, United Kingdom
502.373.1709 Boehringer Ingelheim Investigational Site
Chichester, United Kingdom
502.373.1701 Boehringer Ingelheim Investigational Site
Derby, United Kingdom
502.373.1705 Boehringer Ingelheim Investigational Site
Gateshead, United Kingdom
502.373.1710 Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
502.373.1700 Boehringer Ingelheim Investigational Site
Kirkcaldy, Fife, United Kingdom
502.373.1691 Boehringer Ingelheim Investigational Site
Leeds, United Kingdom
502.373.1699 Boehringer Ingelheim Investigational Site
Leicester, United Kingdom
502.373.1702 Boehringer Ingelheim Investigational Site
Lincoln, United Kingdom
502.373.1697 Boehringer Ingelheim Investigational Site
Liverpool, United Kingdom
502.373.1695 Boehringer Ingelheim Investigational Site
London, United Kingdom
502.373.1693 Boehringer Ingelheim Investigational Site
Manchester, United Kingdom
502.373.1708 Boehringer Ingelheim Investigational Site
Portadown, County Atrim, United Kingdom
502.373.1692 Boehringer Ingelheim Investigational Site
Rugby, United Kingdom
502.373.1696 Boehringer Ingelheim Investigational Site
Sheffield, United Kingdom
502.373.1704 Boehringer Ingelheim Investigational Site
Stirling, United Kingdom
Related Publications (39)
Lee SF, Ramasundarahettige C, Gerstein HC, McIntyre WF, Eikelboom J, O'Donnell MJ, Zhou Y, Bangdiwala SI, Thabane L. Comparison of total event analysis and first event analysis in relation to heterogeneity in cardiovascular trials. BMC Med Res Methodol. 2025 Jun 9;25(1):159. doi: 10.1186/s12874-025-02593-3.
PMID: 40490702DERIVEDNatale P, Palmer SC, Navaneethan SD, Craig JC, Strippoli GF. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2024 Apr 29;4(4):CD006257. doi: 10.1002/14651858.CD006257.pub2.
PMID: 38682786DERIVEDHaring B, Schumacher H, Mancia G, Teo KK, Lonn EM, Mahfoud F, Schmieder R, Mann JFE, Sliwa K, Yusuf S, Bohm M. Triglyceride-glucose index, low-density lipoprotein levels, and cardiovascular outcomes in chronic stable cardiovascular disease: results from the ONTARGET and TRANSCEND trials. Eur J Prev Cardiol. 2024 Feb 15;31(3):311-319. doi: 10.1093/eurjpc/zwad340.
PMID: 37890035DERIVEDCooper TE, Teng C, Tunnicliffe DJ, Cashmore BA, Strippoli GF. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3.
PMID: 37466151DERIVEDBohm M, Schumacher H, Werner C, Teo KK, Lonn EM, Mahfoud F, Speer T, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Laufs U, Williams B, Yusuf S, Mann JFE. Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. Cardiovasc Diabetol. 2022 Jan 20;21(1):12. doi: 10.1186/s12933-021-01429-w.
PMID: 35057807DERIVEDBohm M, Schumacher H, Teo KK, Lonn EM, Lauder L, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S, Mann JFE, Mahfoud F. Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. J Hypertens. 2021 Aug 1;39(8):1602-1610. doi: 10.1097/HJH.0000000000002822.
PMID: 34188004DERIVEDBohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Emrich I, Mancia G, Redon J, Schmieder RE, Sliwa K, Lehrke M, Marx N, Weber MA, Williams B, Yusuf S, Mann JFE. Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. J Hypertens. 2021 Apr 1;39(4):766-774. doi: 10.1097/HJH.0000000000002697.
PMID: 33560052DERIVEDMancia G, Schumacher H, Bohm M, Mann JFE, Redon J, Facchetti R, Schmieder RE, Lonn EM, Teo KK, Yusuf S. Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. J Hypertens. 2020 Oct;38(10):2050-2058. doi: 10.1097/HJH.0000000000002567.
PMID: 32890282DERIVEDDehghan M, Mente A, Rangarajan S, Mohan V, Lear S, Swaminathan S, Wielgosz A, Seron P, Avezum A, Lopez-Jaramillo P, Turbide G, Chifamba J, AlHabib KF, Mohammadifard N, Szuba A, Khatib R, Altuntas Y, Liu X, Iqbal R, Rosengren A, Yusuf R, Smuts M, Yusufali A, Li N, Diaz R, Yusoff K, Kaur M, Soman B, Ismail N, Gupta R, Dans A, Sheridan P, Teo K, Anand SS, Yusuf S. Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. Am J Clin Nutr. 2020 Apr 1;111(4):795-803. doi: 10.1093/ajcn/nqz348.
PMID: 31965140DERIVEDBohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Marx N, Sliwa K, Weber MA, Williams B, Yusuf S. Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. Eur Heart J. 2019 Jul 1;40(25):2032-2043. doi: 10.1093/eurheartj/ehz149.
PMID: 30919899DERIVEDBohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Ukena C, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S. Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. Eur Heart J. 2020 Jan 7;41(2):231-238. doi: 10.1093/eurheartj/ehy808.
PMID: 30590564DERIVEDBohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Weber MA, Williams B, Yusuf S. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017 Jun 3;389(10085):2226-2237. doi: 10.1016/S0140-6736(17)30754-7. Epub 2017 Apr 5.
PMID: 28390695DERIVEDDunkler D, Kohl M, Teo KK, Heinze G, Dehghan M, Clase CM, Gao P, Yusuf S, Mann JF, Oberbauer R. Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union. Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv76-85. doi: 10.1093/ndt/gfv086.
PMID: 26209742DERIVEDBohm M, Schumacher H, Leong D, Mancia G, Unger T, Schmieder R, Custodis F, Diener HC, Laufs U, Lonn E, Sliwa K, Teo K, Fagard R, Redon J, Sleight P, Anderson C, O'Donnell M, Yusuf S. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Hypertension. 2015 Mar;65(3):651-61. doi: 10.1161/HYPERTENSIONAHA.114.04568. Epub 2015 Jan 12.
PMID: 25583157DERIVEDVerdecchia P, Reboldi G, Angeli F, Trimarco B, Mancia G, Pogue J, Gao P, Sleight P, Teo K, Yusuf S. Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease. Hypertension. 2015 Jan;65(1):108-14. doi: 10.1161/HYPERTENSIONAHA.114.04310. Epub 2014 Oct 20.
PMID: 25331850DERIVEDLonn EM, Rambihar S, Gao P, Custodis FF, Sliwa K, Teo KK, Yusuf S, Bohm M. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol. 2014 Feb;103(2):149-59. doi: 10.1007/s00392-013-0644-4. Epub 2013 Dec 20.
PMID: 24356937DERIVEDHeerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur J Prev Cardiol. 2014 Mar;21(3):299-309. doi: 10.1177/2047487313510678. Epub 2013 Nov 4.
PMID: 24191305DERIVEDDunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators. Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. JAMA Intern Med. 2013 Oct 14;173(18):1682-92. doi: 10.1001/jamainternmed.2013.9051.
PMID: 23939297DERIVEDBohm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T, Teo K, Yusuf S. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J. 2013 Aug;166(2):306-314.e7. doi: 10.1016/j.ahj.2013.04.016. Epub 2013 Jun 24.
PMID: 23895814DERIVEDDehghan M, Mente A, Teo KK, Gao P, Sleight P, Dagenais G, Avezum A, Probstfield JL, Dans T, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)/Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Trial Investigators. Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries. Circulation. 2012 Dec 4;126(23):2705-12. doi: 10.1161/CIRCULATIONAHA.112.103234.
PMID: 23212996DERIVEDBarzilay JI, Gao P, Clase CM, Mente A, Mann JF, Sleight P, Yusuf S, Teo KK; OnTARGET/TRANSCEND Investigators. Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures. Clin J Am Soc Nephrol. 2013 Feb;8(2):233-40. doi: 10.2215/CJN.06640712. Epub 2012 Nov 26.
PMID: 23184565DERIVEDKappert K, Bohm M, Schmieder R, Schumacher H, Teo K, Yusuf S, Sleight P, Unger T; ONTARGET/TRANSCEND Investigators. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation. 2012 Aug 21;126(8):934-41. doi: 10.1161/CIRCULATIONAHA.111.086660. Epub 2012 Jul 24.
PMID: 22829023DERIVEDNeumann I, Grassi B. [Critically appraised article]. Rev Med Chil. 2012 Jan;140(1):117-20. Epub 2012 Apr 12. Spanish.
PMID: 22552566DERIVEDVerdecchia P, Dagenais G, Healey J, Gao P, Dans AL, Chazova I, Binbrek AS, Iacobellis G, Ferreira R, Holwerda N, Karatzas N, Keltai M, Mancia G, Sleight P, Teo K, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint TrialTelmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies. J Hypertens. 2012 May;30(5):1004-14. doi: 10.1097/HJH.0b013e3283522a51.
PMID: 22495138DERIVEDRedon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Bohm M, Williams B, Yusoff K, Teo K, Yusuf S; ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012 Jan 3;59(1):74-83. doi: 10.1016/j.jacc.2011.09.040.
PMID: 22192672DERIVEDMancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, Yusoff K, Ryden L, Liu GL, Teo K, Sleight P, Yusuf S. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011 Oct 18;124(16):1727-36. doi: 10.1161/CIRCULATIONAHA.110.008870. Epub 2011 Sep 26.
PMID: 21947289DERIVEDBarzilay JI, Gao P, Ryden L, Schumacher H, Probstfield J, Commerford P, Dans A, Ferreira R, Keltai M, Paolasso E, Yusuf S, Teo K; TRANSCEND Investigators. Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study. Diabetes Care. 2011 Sep;34(9):1902-7. doi: 10.2337/dc11-0545. Epub 2011 Jul 25.
PMID: 21788624DERIVEDTobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JF; ONTARGET and TRANSCEND Investigators. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation. 2011 Mar 15;123(10):1098-107. doi: 10.1161/CIRCULATIONAHA.110.964171. Epub 2011 Feb 28.
PMID: 21357827DERIVEDBarzilay JI, Gao P, O'Donnell M, Mann JF, Anderson C, Fagard R, Probstfield J, Dagenais GR, Teo K, Yusuf S; ONTARGET and TRANSCEND Investigators. Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies. Arch Intern Med. 2011 Jan 24;171(2):142-50. doi: 10.1001/archinternmed.2010.502.
PMID: 21263104DERIVEDDans AL, Teo K, Gao P, Chen JH, Jae-Hyung K, Yusoff K, Chaithiraphan S, Zhu J, Lisheng L, Yusuf S; Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial Investigators. In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events. PLoS One. 2010 Dec 21;5(12):e13694. doi: 10.1371/journal.pone.0013694.
PMID: 21200437DERIVEDAnderson C, Teo K, Gao P, Arima H, Dans A, Unger T, Commerford P, Dyal L, Schumacher H, Pogue J, Paolasso E, Holwerda N, Chazova I, Binbrek A, Young J, Yusuf S; ONTARGET and TRANSCEND Investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011 Jan;10(1):43-53. doi: 10.1016/S1474-4422(10)70250-7. Epub 2010 Oct 25.
PMID: 20980201DERIVEDBohm M, Baumhakel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation. 2010 Mar 30;121(12):1439-46. doi: 10.1161/CIRCULATIONAHA.109.864199. Epub 2010 Mar 15.
PMID: 20231536DERIVEDVerdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S; ONTARGET/TRANSCEND Investigators. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation. 2009 Oct 6;120(14):1380-9. doi: 10.1161/CIRCULATIONAHA.109.865774. Epub 2009 Sep 21.
PMID: 19770395DERIVEDSleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Bohm M, Williams B, Pogue J, Koon T, Yusuf S; ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009 Jul;27(7):1360-9. doi: 10.1097/HJH.0b013e32832d7370.
PMID: 19506526DERIVEDMann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Ryden L, Yu CM, Teo KK, Yusuf S; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009 Jul 7;151(1):1-10, W1-2. doi: 10.7326/0003-4819-151-1-200907070-00122. Epub 2009 May 18.
PMID: 19451556DERIVEDTelmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29.
PMID: 18757085DERIVEDMann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008 Aug 16;372(9638):547-53. doi: 10.1016/S0140-6736(08)61236-2.
PMID: 18707986DERIVEDONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31.
PMID: 18378520DERIVEDHeld C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K; ONTARGET/TRANSCEND Investigators. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation. 2007 Mar 20;115(11):1371-5. doi: 10.1161/CIRCULATIONAHA.106.661405. Epub 2007 Mar 5.
PMID: 17339550DERIVED
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Limitations and Caveats
Only non-serious Adverse Events (AE) which lead to discontinuation of study medication were assessed and collected; the frequency was under 5%. Non-serious AEs per se were not assessed or collected.
Results Point of Contact
- Title
- Boehringer Ingelheim Call Center
- Organization
- Boehringer Ingelheim Pharmaceuticals
Study Officials
- STUDY CHAIR
Boehringer Ingelheim
Boehringer Ingelheim
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 9, 2005
First Posted
September 12, 2005
Study Start
November 1, 2001
Primary Completion
June 1, 2008
Last Updated
May 20, 2014
Results First Posted
August 25, 2009
Record last verified: 2014-05